Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

Company Overview

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Key Stats

• Today's Range: $10.25 to $10.25
• 50-Day Range: $10.14 to $10.35
• 52-Week Range: $1.40 to $10.44
• Volume: N/A
• Average Volume: 1.32 million shs
• Market Capitalization: $744.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRCL Stock Analysis - Frequently Asked Questions

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The business had revenue of $0.06 million for the quarter.

When did Gracell Biotechnologies IPO?

Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

What other stocks do shareholders of Gracell Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gracell Biotechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/14/2021
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRCL
• CUSIP: N/A
• CIK: 1826492
• Web: www.gracellbio.com
• Phone: 86-512-6262-6701
• Fax: N/A
• Employees: 314
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-88,080,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.40%
• Return on Assets: -31.24%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 7.73
• Quick Ratio: 7.73

Sales & Book Value

• Annual Sales: $60,000.00
• Price / Sales: 12,415.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.95 per share
• Price / Book: 3.47

Miscellaneous

• Outstanding Shares: 72,678,000
• Free Float: 52,328,000
• Market Cap: $744.95 million
• Optionable: Optionable
• Beta: -0.33